PaxMedica announces receives notification to grant patent right in China

PaxMedica (PXMD) has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism. Howard Weisman, CEO of PaxMedica commented, “This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been approved, since it was first used in humans over 100 years ago. This patent covers claims for treating neurological disorders, such as autism, using a novel formulation of suramin for intranasal delivery, rather than its current infusion dosing. Similar patent applications are filed in multiple, sovereign jurisdictions, and we will continue to pursue claims in other territories, including the United States.”